Share chart Resverlogix Corp.
Extended chart
Simple chart
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. more details| ISIN | CA76128M1086 |
|---|---|
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.resverlogix.com |
| Цена ао | 0.03 |
| Change price per day: | 0% (0.03) |
|---|---|
| Change price per week: | 0% (0.03) |
| Change price per month: | 0% (0.03) |
| Change price per 3 month: | 0% (0.03) |
| Change price per half year: | -25% (0.04) |
| Change price per year: | -25% (0.04) |
| Change price per 3 year: | -91.89% (0.37) |
| Change price per 5 year: | -96.84% (0.95) |
| Change price per year to date: | 0% (0.03) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, President, CEO & Secretary | 370k | |
| Mr. Aaron Bradley Cann C.A., CPA, CBV | Chief Financial Officer | 206.38k | |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer | 183.09k | |
| Dr. Michael Sweeney M.D. | Senior Vice President of Clinical Development | 374.66k | 1961 (64 years) |
Address: Canada, Calgary. AB TE L, 4820 Richard Road SW - open in Google maps, open in Yandex maps
Website: https://www.resverlogix.com
Website: https://www.resverlogix.com
